EUROPEAN UROLOGY 60 (2011)
|
|
- Laurence Boone
- 8 years ago
- Views:
Transcription
1 EUROPEAN UROLOGY 60 (2011) available at journal homepage: Platinum Priority Kidney Cancer Editorial by Simon P. Kim and R. Houston Thompson on pp of this issue A Stage-for-Stage and Grade-for-Grade Analysis of Cancer-Specific Mortality Rates in Renal Cell Carcinoma According to Age: A Competing-Risks Regression Analysis Maxine Sun a,y, *, Firas Abdollah b,y, Marco Bianchi a,b, Quoc-Dien Trinh a,c, Claudio Jeldres a,d, Zhe Tian a, Shahrokh F. Shariat e, Hugues Widmer d, Kevin Zorn d, Mani Menon c, Francesco Montorsi b, Paul Perrotte d, Pierre I. Karakiewicz a,d a Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; b Department of Urology, Vita Salute San Raffaele University, Milan, Italy; c Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA; d Department of Urology, University of Montreal Health Center, Montreal, Canada; e Department of Urology, Weill Medical College, Cornell University, New York, NY, USA Article info Article history: Accepted July 27, 2011 Published online ahead of print on August 5, 2011 Keywords: Renal cell carcinoma Age Cancer-specific mortality Nephrectomy Competing-risks regression Abstract Background: The association of advanced age and cancer control outcomes shows discordant findings. Objective: To evaluate the effect of age on cancer control outcomes in a large population-based cohort of patients diagnosed with renal cell carcinoma (RCC) of all stages. Design, setting, and participants: Using the Surveillance Epidemiology and End Results database, patients with RCC were identified. The population was stratified according to age: < 50, 50 59, 60 69, 70 79, and 80 yr. The effect of age on cancer control outcomes was evaluated using competing-risks regression models. Analyses were repeated stage for stage and grade for grade. Measurements: Cancer-specific mortality (CSM) was measured. Results and limitations: Age categories 50 59, 60 69, 70 79, and 80 yr respectively portended a 1.4-, 1.5-, 1.6-, and 1.9-fold higher risk of CSM than age category <50 yr (all p < 0.001). The effect of advanced age was particularly detrimental in patients with stage I disease: 1.8-, 2.3-, 3.2-, and 3.8-fold higher CSM risk for the same age groups, respectively (all p < 0.001). The effect of age on CSM was at its peak in patients with stage I, low-grade RCC (1.6-, 2.2-, 3.6-, and 4.3-fold, respectively; all p < 0.001) and remained elevated in stage I, high-grade RCC (2.2-, 2.6-, 2.4-, and 3.0-fold higher, respectively; all p < 0.05). Conversely, its effect was virtually absent in patients with stage II IV RCC. Conclusions: Our data suggest that stage I RCC may behave in a more aggressive fashion in elderly patients. Further studies are required to confirm the current findings. Crown Copyright # 2011 Published by Elsevier B.V. on behalf of European Association of Urology. All rights reserved. y Both authors contributed equally to the manuscript. * Corresponding author. Cancer Prognostics and Health Outcomes Unit, CHUM, 1058 rue St-Denis, Montreal, QC, H2X 3J4, Canada. Tel ext 35335; Fax: address: mcw.sun@umontreal.ca (M. Sun). 1. Introduction The incidence of renal cell carcinoma (RCC) continues to increase [1]. In the United States, approximately new cases were diagnosed in 2010 [2]. Despite the innovations in the treatment management of RCC in recent years, mortality rates have continued to rise [1,3]. It is known that the majority of newly diagnosed RCC patients are aged or yr. Given that the average life expectancy has steadily increased in the United States [4], it may be expected that more elderly patients will be diagnosed with RCC in the upcoming years /$ see back matter Crown Copyright # 2011 Published by Elsevier B.V. on behalf of European Association of Urology. All rights reserved. doi: /j.eururo
2 EUROPEAN UROLOGY 60 (2011) As with several other urologic malignancies, age represents an independent prognostic factor of worse survival in patients with RCC [5 10]. In a pertinent study, Hollingsworth et al. [10] examined the Surveillance Epidemiology and End Results (SEER) database to evaluate cancer-specific mortality (CSM) in patients according to age groups. Within that study, only surgically managed localized and regional RCC patients were included. The authors recorded an increasing risk of CSM with more advanced age in a univariable analysis. That being said, the effect of age was not examined with adjustment for other important tumor characteristics, such as stage and grade. The current study has several objectives. First, we examined RCC patients according to different age decades. Second, we sought to perform a stage-for-stage and grade-forgrade analysis of CSM rates according to age groups. Finally, since a large proportion of elderly patients may die of causes other than cancer, we used competing-risks methodology to account for this potential confounder in all our analyses. 2. Materials and methods 2.1. Data source The SEER program database, as reported by the US National Cancer Institute, was used to identify the study population. The SEER program collects patient demographics and publishes cancer incidence and survival data from population-based cancer registries, covering approximately 26% of the US population. Data from 1988 to 2006 from 17 SEER registries were abstracted Study population Individuals with histologically confirmed RCC were identified using the International Classification of Diseases for Oncology [ICD-O] (C67.0, C.67.9). Patients <25 yr were removed from the analysis. All autopsy or death certificate cases were excluded from the current study. Only patients with the main histologic subtypes (clear cell, papillary, chromophobe) were included. Patients with missing tumor (T) or node (N) stage information wereremoved aswellas patientswithnoinformation ondistant metastasis status. This method resulted in a total of RCC patients of all stages Description of covariates Patient age at diagnosis was classified according to decades, similar to a previous study: <50, 50 59, 60 69, 70 79, and 80 yr [10]. Other patient characteristics include race (white, black, other) and year of diagnosis tertiles ( , , ). Treatment type was categorized aspatientswho were surgicallymanaged(partialnephrectomy [PN] vs radical nephrectomy [RN]) or patients for whom surgery was not recommended. The latter categorization was identified via the absence of a concomitant code for RN or PN. Several clinical and pathologic characteristics were available within the SEER database, namely, tumor size (continuously coded), histologic subtype (clear cell, papillary, chromophobe), and Fuhrman grade (low grade [I II], high grade [III IV]). Table 1 Descriptive characteristics of patients with renal cell carcinoma, Surveillance Epidemiology and End Results, Variable <50 yr (n = 6603) yr (n = 8922) yr (n = 9877) yr (n = 8294) >80 yr (n = 2637) p value Gender <0.001 Male 4122 (62.5) 5908 (66.2) 6342 (64.2) 4988 (60.1) 1458 (55.3) Female 2481 (37.6) 3114 (34.9) 3535 (35.8) 3306 (39.9) 1179 (44.7) Race <0.001 White 5407 (81.9) 7398 (82.9) 8398 (85.0) 7231 (87.2) 2370 (89.9) Black 741 (11.2) 980 (11.0) 875 (8.9) 573 (6.9) 139 (5.3) Other 455 (6.9) 544 (6.1) 604 (6.1) 490 (5.9) 128 (4.9) Surgery type <0.001 Radical nephrectomy 5257 (79.6) 7326 (82.1) 8132 (82.3) 7064 (85.2) 2284 (86.6) Partial nephrectomy 1287 (19.5) 1504 (16.9) 1619 (16.4) 1071 (12.9) 238 (9.0) Nonsurgical management 59 (0.9) 92 (1.0) 126 (1.3) 159 (1.9) 115 (4.4) Histologic subtype <0.001 Clear cell 5841 (88.5) 7906 (88.6) 8732 (88.4) 7335 (88.4) 2273 (86.2) Chromophobe 276 (4.2) 256 (2.9) 248 (2.5) 225 (2.7) 102 (3.9) Papillary 486 (7.4) 760 (8.5) 897 (9.1) 734 (8.8) 262 (9.9) Tumor grade <0.001 I II 4943 (74.9) 6338 (71.0) 7051 (71.4) 5895 (71.1) 1825 (69.2) III IV 1660 (25.1) 2584 (29.0) 2826 (28.6) 2399 (28.9) 812 (30.8) T stage <0.001 T (67.6) 5729 (64.2) 6334 (64.1) 5339 (64.4) 1608 (61.0) T (17.2) 1348 (15.1) 1276 (12.9) 963 (11.6) 313 (11.9) T3 943 (14.3) 1753 (19.6) 2148 (21.7) 1896 (22.9) 678 (25.7) T4 57 (0.9) 92 (1.0) 119 (1.2) 96 (1.2) 38 (1.4) N stage N (96.3) 8594 (96.3) 9484 (96.0) 8050 (97.1) 2530 (95.9) N (3.7) 328 (3.7) 393 (4.0) 244 (2.9) 107 (4.1) M stage <0.001 M (97.6) 8572 (96.1) 9543 (96.6) 8100 (97.7) 2578 (97.8) M1 160 (2.4) 350 (3.9) 334 (3.4) 194 (2.3) 59 (2.2) AJCC stage <0.001 I 4408 (66.8) 5639 (63.2) 6247 (63.2) 5258 (63.4) 1574 (59.7) II 1077 (16.3) 1238 (13.9) 1184 (12.0) 902 (10.9) 295 (11.2) III 752 (11.4) 1417 (15.9) 1753 (17.7) 1683 (20.3) 597 (22.6) IV 366 (5.5) 628 (7.0) 693 (7.0) 451 (5.4) 171 (6.5) T = tumor; N = node; M = metastasis; AJCC = American Joint Committee on Cancer.
3 1154 EUROPEAN UROLOGY 60 (2011) The TNM 2002stagingsystem wasusedtoclassifypatientsaccording tothe American Joint Cancer Committee (AJCC) stages: I (T1N0M0), II (T2N0M0), III (T1 3N0 1M0), and IV (T4N0 1M0 1) [11]. The cause of death was defined according to the SEER-specific cause of death code (29010). Deaths from RCC were coded as CSM events. All other deaths were considered as other-cause mortality (OCM) Statistical analysis Frequencies and proportions were generated for categorical variables. We relied on the competing-risks regression methodology to assess CSM, as described by Fine and Gray [12]. The latter accounts for the effect of OCM and provides the most unbiased estimates of CSM. Age-stratified cumulative incidence CSM rates were generated for different groups and compared with the Gray test [13]. Subsequently, univariable and multivariable competing-risks regression models were used to test the effect of age (at <50, 50 59, 60 69, 70 79, and 80 yr) on CSM rates. Covariates included gender, race, year of diagnosis, tumor size, histologic subtype, AJCC stage, and Fuhrman grade. To assess the magnitude of the effect related to age, we repeated all multivariable competing-risks regression models after stratifying according to AJCC stage (stages I, II, III, and IV) and tumor grade (I II vs III IV). Finally, to reduce the bias associated with pathologic staging data, the aforementioned analyses were repeated within patients who underwent RN. Prior to fitting the competing-risks models, the proportional cause-specific hazards assumption, theproportionalityofthe hazards ofthecumulativeincidence function assumption, and the linearity assumption were tested [14]. All statistical tests were performed using the R statistical package (v ) or SPSS (Chicago, IL, USA). Finally, all tests were two-sided, with a significance level set at p < Results Overall, RCC patients were identified between 1988 and 2006 (Table 1). Several baseline characteristics differed according to age groups. For example, more females were aged 80 yr relative to those aged <50 yr (45% vs 38%; odds ratio [OR]: 1.35; p < 0.001). A lower proportion of black race was recorded in persons aged 80 yr (5% vs 11%; OR: 0.44; p < 0.001). Patients of different age groups also differed according to clinical and pathologic characteristics. In general, patients aged 80 yr had a more advanced T stage than patients aged <50 yr (T4: 1.4% vs 0.9%; OR: 1.68; p=0.01), a higher proportion of node-positive patients (4.1% vs 3.7%; OR: 1.1; p = 0.5), and more advanced Fuhrman grade (III IV: 31% vs 25%; OR: 1.33; p < 0.001). Patients aged yr had a higher rate of distant metastasis than patients aged <50 yr (3.4% vs 2.9%; OR: 1.6; p < 0.001). The number of deaths from CSM and OCM for the entire cohort, stratified according to age group and disease stage, is illustrated in Table 2. The overall respective 5- and 10-yr CSM rates, after accounting for OCM, were 8.7% and 12.5% for patients aged <50, 12.4% and 18.7% for patients aged 50 59, 13.2% and 20.7% for patients aged 60 69, 14.8% and 23.9% for patients aged 70 79, and 18.0% and 26.2% for patients aged 80 yr (all p < 0.001, Fig. 1). When cumulative incidence CSM rates were stratified according to AJCC stage, older age continuously portended to higher CSM rates than their younger counterparts (data not shown). The multivariable age-specific hazard ratios (HRs) predicting CSM in the entire cohort and stratified according to AJCC stage are depicted in Figure 2A 2E. Patients aged 50 59, 60 69, 70 79, and 80 yr demonstrated a higher rate of CSM than their counterparts aged <50 yr (HR: 1.4, 1.5, 1.6, and 1.9, respectively; all p < 0.001), even after accounting for OCM (Fig. 2A). The risk of CSM was 1.8-, 2.3-, 3.2-, and 3.8-fold higher, respectively, for the same age groups within stage I RCC (all p < 0.001; Fig. 2B); 1.4-, 1.4-, 1.6-, and 1.5-fold higher, respectively, for stage II RCC (all Table 2 Cause-of-death information within the entire population and stratified according to age group and renal cell carcinoma stage Overall <50 yr yr yr yr 80 yr Entire cohort Patients, no Total deaths, no Renal cell carcinoma Other-cause mortality Stage I Patients, no Total deaths, no Renal cell carcinoma Other-cause mortality Stage II Patients, no Total deaths, no Renal cell carcinoma Other-cause mortality Stage III Patients, no Total deaths, no Renal cell carcinoma Other-cause mortality Stage IV Patients, no Total deaths, no Renal cell carcinoma Other-cause mortality
4 [(Fig._1)TD$FIG] EUROPEAN UROLOGY 60 (2011) Fig. 1 Cumulative incidence plot depicting cancer-specific mortality (CSM) rates, stratified according to age categories (all Gray test p < 0.001) for (A) the entire population and for (B) stage I, (C) stage II, (D) stage III, and (E) stage IV renal cell carcinoma. p < 0.05; Fig. 2C); 1.1-, 1.1-, 1.3-, and 1.4-fold higher for stage III RCC (all p < 0.05, except for ages and yr; Fig. 2D); and 1.2-, 1.2-, 1.1-, and 1.4-fold higher respectively, for stage IV RCC (all p < 0.05, except for ages and yr; Fig. 2E). Similar findings were recorded in two subanalyses of patients with T1aN0M0 and T1 4N0M0 RCC. Specifically, the risk of CSM for the two groups was 1.5-, 3.0-, 4.8-, and 8.5-fold and 1.4-, 1.5-, 1.8-, and 2.1-fold higher in patients aged 50 59, 60 69, 70 79, and 80 yr, respectively (all p < 0.001). Figure 3A 3J illustrates the stage-for-stage and gradefor-grade age-specific HRs predicting CSM. Regardless of stage, more advanced age portended to higher CSM among patients with low- and high-grade disease. For example, relative to patients aged <50 yr, the risk of CSM was 1.4-, 1.6-, 2.1-, and 2.4-fold higher in patients with low-grade RCC, aged 60 69, 70 79, and 80 yr, respectively (all p < 0.001; Fig. 3A). Similarly, in patients with high-grade RCC, the respective HRs for the same age groups were 1.3, 1.3, 1.4, and 1.5, respectively (all p < 0.001, Fig. 3B). Within stage I, low-grade RCC (HR: 1.6, 2.2, 3.6, and 4.3) and highgrade RCC (HR: 2.2, 2.6, 2.4, and 3.0), more advanced age portended to higher CSM rates (all p 0.001; Fig. 3C and 3D). In stage II, more advanced age demonstrated significantly worse survival only in low-grade RCC (Fig. 3E). In all other stage and grade combinations, age failed to reach independent predictor status (Fig. 3G 3J). In a subanalysis of patients treated with RN, virtually the same results were recorded (Fig. 4). 4. Discussion Our objective was to examine the effect of age on CSM in patients with RCC of all stages, regardless of the treatment modality and after accounting for OCM. To date, the effect of age has never been studied using this type of appraisal. Previous age analyses were invariably performed on highly select patient subsets, in which the inclusion criteria relied on disease stage or treatment type, or both. These limitations undermined the generalizability of the findings. Most important, no study assessed the effect of age in a stage-for-stage and grade-for-grade fashion. In the current analysis, we attempted to circumvent these limitations. We included surgically and nonsurgically managed patients, as well as all disease stages. Finally, we used multivariable time-to-event modeling that controlled for other competing events. This consideration is essential in analyses addressing age, since a large proportion of elderly patients may succumb to OCM, which may critically confound the results. Our results first focused on the entire patient cohort. Subsequently, the data were stratified according to AJCC stage and tumor grade. Finally, the stratified analyses were repeated exclusively on patients treated with RN. The overall results showed that more advanced patient age predisposes to higher CSM rates, even after adjusting for all covariates, including that of OCM. Stage-specific analyses showed that the most substantial effect of advanced age on CSM was observed in individuals with stage I RCC.
5 1156 [(Fig._2)TD$FIG] EUROPEAN UROLOGY 60 (2011) [(Fig._3)TD$FIG] Fig. 2 Multivariable competing-risks regression predicting cancerspecific mortality (CSM) in patients with renal cell carcinoma of (A) all stages, (B) stage I, (C) stage II, (D) stage III, and (E) stage IV, stratified according to age categories. The x-axes denote the hazard ratios. The y- axes denote the age categories. The referent (ref.) category is patients aged <50 yr (hazard ratio: 1.0) across all examined subcohorts. The 95% confidence intervals are represented for each category. Furthermore, the effect of age was stronger in patients with low-grade RCC, regardless of stage. In other stages, the effect was substantially less. That being said, the effect of advanced age, although statistically significantly associated with worse survival, may be less pronounced in patients with stage III or IV RCC given the aggressive nature of the disease, beyond that of stage and grade, in younger patients, as was recently examined [15]. Fig. 3 Multivariable competing-risks regression predicting cancerspecific mortality (CSM) in patients with renal cell carcinoma of all stages, stage I, stage II, stage III, and stage IV, stratified according to low grade (I II) and high grade (III IV). The x-axes denote the hazard ratios. The y-axes denote the age categories. The referent (ref.) category is patients aged <50 yr (hazard ratio: 1.0) across all examined subcohorts. The 95% confidence intervals are represented for each category. Further stage-for-stage and grade-for-grade substratification revealed interesting findings. Specifically, the effect of advanced age in stage I patients is most prominent among individuals with low-grade tumors. It may be postulated that the detrimental effect of advanced age in individuals with low-grade disease was largely attributable to patients who were nonsurgically managed. Unfortunately, because
6 [(Fig._4)TD$FIG] EUROPEAN UROLOGY 60 (2011) Fig. 4 Multivariable competing-risks regression predicting cancerspecific mortality (CSM) in patients treated with radical nephrectomy for renal cell carcinoma of all stages, stage I, stage II, stage III, and stage IV, stratified according to low grade (I II) and high grade (III IV). The x-axes denote the hazard ratios. The y-axes denote the age categories. The referent (ref.) category is patients aged <50 yr (hazard ratio: 1.0) across all examined subcohorts. The 95% confidence intervals are represented for each category. of the low number of cases within the current cohort, we were unable to examine the effect of CSM in exclusively nonsurgically managed patients. Nonetheless, the detrimental effect of more advanced age remained highly important in surgically managed individuals with stage I low-grade tumors. Taken together, these data imply that the effect of more advanced age on CSM is particularly important in patients with stage I RCC and/or low-grade tumors. In contrast, the effect of age becomes secondary to disease characteristics in patients with tumors of more advanced stage (stage II IV) and/or high grade (III IV). These findings are particularly important given the rising incidence of localized RCC and increasing life expectancy of the population [16]. Several explanations may be proposed as to why the prognosis of elderly patients with low-stage and low-grade disease is significantly worse than that of their younger counterparts. First, the natural history of RCC may be more aggressive in the elderly. Second, elderly patients may be subject to a delay in treatment and suboptimal follow-up after diagnosis, particularly in the context of small renal masses, for which elderly patients may be more likely to be investigated or treated in a less timely fashion. Third, health insurance provider differences between elderly and younger patients may exist. Specifically, younger patients may be subject to periodic health examinations, whereas retired individuals may undergo less routine examinations. That said, given that the SEER database does not contain any information on tumor characteristics beyond stage and grade, and given that we did not have the time interval between diagnosis and treatment or health insurance information, the explanations proposed remain speculative. Furthermore, from a practical perspective, the current data suggest that active surveillance may not always be suitable in the elderly with stage I RCC, regardless of the grade of the tumor. This observation contradicts existing North American guidelines, in which older age is considered as a condition allowing less aggressive treatment management [17,18]. In contrast, the most up-to-date European guidelines do not account for the effect of age on prognosis in patients with RCC [19]. Currently, the rationale for active surveillance derives from the hypothesis that surgical intervention for small renal masses may not confer a survival advantage in elderly patients. For example, the Cleveland Clinic Foundation demonstrated a lack of survival benefit of both PN (HR: 0.67; 95% CI, ) and RN (HR: 0.75; 95% CI, ) relative to active surveillance in patients aged 75 yr ( p=0.2) [20]. Moreover, the majority of small renal masses may be benign or low-grade disease with indolent behavior [21]. However, existing series on active surveillance are limited by small sample size and short follow-up, and they originate from single-institution data. Furthermore, the current study as well as previously published reports showed that more advanced age represents a strong risk factor for CSM in patients with localized RCC [22,23]. However, more advanced age is a predictor for surveillance [20]. Although existing paradigms suggest that there is overtreatment in localized RCC, undertreatment represents an equally important consideration. Consequently, at least in some elderly patients with localized RCC, the potential for curative disease management should not be denied. More historical prognostic models for prediction of CSM do not incorporate age. Specifically, the University of California, Los Angeles, system opted for the inclusion of performance status in its model over age [24]. Similarly, the Mayo Clinic series relies on disease stage, tumor grade, and necrosis to generate a score to predict outcome [25]. A postoperative nomogram for prediction of recurrence also fails to account for age, as well as performance status [26]. However, more contemporary models have revealed important prognostication for patient age at diagnosis.
7 1158 EUROPEAN UROLOGY 60 (2011) For example, Karakiewicz et al. [9] developed a highly accurate preoperative nomogram predicting CSM-free survival using age, sex, symptoms, tumor size, tumor stage, and distant metastasis status. In summary, there is a growing but nonetheless discordant body of literature focusing on the relationship between age and CSM in RCC. Some studies have shown an association between young age and survival. For example, Sánchez-Ortiz et al. [27] recorded a survival benefit in patients aged 40 yr relative to those aged yr. Others recorded a 5-yr CSM-free survival benefit in younger patients (30 39 yr) versus older patients (70 79 yr, p=0.01) for localized RCC [5]. Jung et al. [28], as well as Komai et al. [7], recently corroborated these findings within two single institutional reports. Conversely, Thomson et al. [29] and Gillett et al. [30] reported a lack of statistically significant difference between young and old individuals in regard to CSM. Similarly, Hollingsworth et al. [10] failed to detect a significant difference for CSM for individuals with advanced age using univariable competing-risks analyses. Our manuscript is not without limitations. First, the SEER database does not allow the differentiation between sporadic versus hereditary RCC. This information is important, given that when RCC is diagnosed in patients aged <50 yr, a hereditary case may be suspected. Since the natural history of RCC in von Hippel-Lindau disease is different between hereditary and sporadic RCC [31], this differentiation may have provided important insights into the difference in prognosis according to age. Second, the version of the SEER database used does not contain information on baseline comorbidity status or performance status, both of which are important in the selection of surgical candidates. The lack of comorbidities represents an important limitation to the current study. The combination of age and comorbidities allows the estimation of life expectancy, which is an essential proxy for determining the survival outcomes of patients with RCC [16]. The use of competing-risks regression analysis may have compensated for the lack of baseline comorbidity and performance status. Nonetheless, the sole adjustment for OCM remains insufficient. Future studies examining the effect of age on survival should attempt to incorporate this information. Third, information on other minimally invasive treatment approaches (eg, percutaneous radio frequency ablation, cryoablation, microwave ablation, laser ablation, and high-intensity focused ultrasound ablation), immunotherapy, and targeted therapy was not available within the current database. This limitation may have induced a selection bias. Nonetheless, previous investigators have shown that thermal ablation was low (3.8%) in the SEER database [32]. Moreover, older patients were more likely to receive such treatment relative to their younger counterparts. Consequently, worse survival in elderly patients may not be entirely explained according to such bias. Fourth, we were unable to examine the effect of age on patients who were exclusively nonsurgically managed because of the small sample size. Existing literature on the role of active surveillance remains controversial. No study examining active surveillance and survival with adequate sample size and sufficient follow-up time exists. Fifth, the lack of information on adjuvant therapies likely affected survival data, especially in patients with more advanced disease stage. Sixth, as in all retrospective observational data, a coding misattribution with regard to cause of death may have been operational. However, this misattribution should be equally applicable to all patients, regardless of their age or stage of disease. Thus the limitation cannot completely explain the observed effect, where more advanced age portended to a worse survival, particularly in patients with low-stage/low-grade disease. Similarly, lack of central pathology, other coding misattribution, and entry error may have been operational. However, all previous studies examining population-based cohorts were also affected by this limitation [10,23,33]. 5. Conclusions The current data show that increasing age is an important prognostic factor for worse survival outcomes in patients with low-stage, low-grade RCC, despite adjusting for available covariates, including OCM. However, given the lack of information on comorbidities and performance status, the current study cannot recommend an undiscriminated surgical approach for all elderly patients with a localized disease. Nonetheless, further studies are necessary to confirm or refute the current findings. Author contributions: Maxine Sun had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Sun, Abdollah, Bianchi, Karakiewicz. Acquisition of data: Sun, Tian. Analysis and interpretation of data: Sun, Abdollah, Trinh, Jeldres, Karakiewicz. Drafting of the manuscript: Sun, Abdollah, Karakiewicz. Critical revision of the manuscript for important intellectual content: Jeldres, Shariat, Widmer, Zorn, Menon, Montorsi, Perrotte, Karakiewicz. Statistical analysis: Sun, Tian. Obtaining funding: Perrotte, Karakiewicz. Administrative, technical, or material support: Perrotte, Karakiewicz. Supervision: Shariat, Menon, Montorsi, Perrotte, Karakiewicz. Other (specify): None. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Pierre I. Karakiewicz is partially supported by the University of Montreal Health Centre Urology Specialists, Fonds de la Recherche en Santé du Québec, the University of Montreal Department of Surgery and the University of Montreal Health Centre (CHUM) Foundation. Funding/Support and role of the sponsor: None. References [1] Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011;59:
8 EUROPEAN UROLOGY 60 (2011) [2] Jemal A, Bray F, Center M, et al. Global cancer statistics. CA Cancer J Clin 2011;61: [3] Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98: [4] U.S. interim projections by age, sex, race, and Hispanic origin: US Census Bureau Web site. gov/population/www/projections/usinterimproj. [5] Scoll BJ, Wong Y-N, Egleston BL, et al. Age, tumor size and relative survivalofpatientswithlocalizedrenal cellcarcinoma: a Surveillance, Epidemiology and End Results analysis. J Urol 2009;181: [6] Muramaki M, Miyake H, Sakai I, et al. Age at diagnosis as a powerful predictor for disease recurrence after radical nephrectomy in Japanese patients with pt1 renal cell carcinoma. Int J Urol 2011;18: [7] Komai Y, Fujii Y, Iimura Y, et al. Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma. Urology 2011;77: [8] Karakiewicz PI, Jeldres C, Suardi N, et al. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2008;2: [9] Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009;55: [10] Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007;109: [11] Sobin L, Gospodarowicz M, Wittekind C, editors. International Union Against Cancer (UICC). TNM classification of malignant tumors. ed 6. Oxford, UK: Wiley-Blackwell; [12] Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: [13] Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16: [14] Pintilie M. Competing risks: a practical perspective. Hoboken, NJ: John Wiley & Sons; [15] Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-basedanalysis. Ann Oncol. Inpress. [16] Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001;285: [17] Campbell S, Novick A, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182: [18] Kidney cancer (cited V ). National Comprehensive Cancer Network Web site. gls/f_guidelines.asp#site. [19] Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58: [20] Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116: [21] Volpe A, Cadeddu JA, Cestari A, et al. Contemporary management of small renal masses. Eur Urol 2011;60: [22] Lughezzani G, Sun M, Budäus L, et al. Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J Clin Oncol 2010;28: [23] Kutikov A, Egleston BL, Wong Y-N, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28: [24] Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: [25] Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007;177: [26] Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63 7. [27] Sánchez-Ortiz RF, Rosser CJ, Madsen LT, et al. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol 2004;171: [28] Jung E-J, Lee HJ, Kwak C, et al. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology 2009;73: [29] Thompson RH, Ordonez MA, Iasonos A, et al. Renal cell carcinoma in young and old patients is there a difference? J Urol 2008;180: , discussion [30] Gillett MD, Cheville JC, Karnes RJ, et al. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol 2005;173: [31] Clark PE, Cookson MS. The von Hippel-Lindau gene: turning discovery into therapy. Cancer 2008;113: [32] Choueiri TK, Schutz FAB, Hevelone ND, et al. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology 2011;78: [33] Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a populationbased cohort study. Cancer 2009;115:
Intensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study
Annals of Oncology Advance Access published February 22, 2014 1 Intensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationMetastatic Renal Cell Carcinoma Risk According to Tumor Size
Metastatic Renal Cell Carcinoma Risk According to Tumor Size R. Houston Thompson, Jennifer R. Hill, Yuriy Babayev, Angel Cronin, Matt Kaag, Shilajit Kundu, Melanie Bernstein, Jonathan Coleman, Guido Dalbagni,
More informationBACKGROUND. Evidence exists to suggest a pattern of increasing early diagnosis
78 Renal Cell Cancer Stage Migration Analysis of the National Cancer Data Base Christopher J. Kane, MD 1,2 Katherine Mallin, PhD 3 Jamie Ritchey, MPH 3 Matthew R. Cooperberg, MD, MPH 4 Peter R. Carroll,
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationThe Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney
Opposing Views The Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney NEPHRON SPARING SURGERY When a patient is seated in front of you with a6cm contrast enhancing
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationRenal Cell Carcinoma: Prognostic Factors and Patient Selection
european urology supplements 6 (2007) 477 483 available at www.sciencedirect.com journal homepage: www.europeanurology.com Renal Cell Carcinoma: Prognostic Factors and Patient Selection Arie S. Belldegrun
More informationOncological outcome of surgical treatment in 336 patients with renal cell carcinoma
窑 Original Article 窑 Chinese Journal of Cancer Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma Zhi Ling Zhang,2, Yong Hong Li,2, Yong Hong Xiong 3, Guo Liang Hou,2,
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationCHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationTravel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationRCC accounts for 3% of all malignant tumors and now
Prognostic Value of Thrombocytosis in Renal Cell Carcinoma Karim Bensalah, Emmanuelle Leray, Patricia Fergelot, Nathalie Rioux-Leclercq, Jacques Tostain, François Guillé and Jean-Jacques Patard* From the
More informationSignificant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell Carcinoma at a Private and Public Hospital in Brazil
Clinical Urology Heterogeneity to renal cell carcinoma International Braz J Urol Vol. 37 (5): 584-590, September - October, 2011 Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell
More informationSurvival among Black and White Patients with Renal Cell Carcinoma in an Equal-Access Health Care System. Kangmin Zhu 1,4*
Survival among Black and White Patients with Renal Cell Carcinoma in an Equal-Access Health Care System Jie Lin 1*, Shelia H. Zahm 2, Craig D. Shriver 1,3,4, Mark Purdue 2, Katherine A. McGlynn 2, Kangmin
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationProstate Cancer. Racial Differences in Prostate Cancer Treatment Outcomes. Prostate Cancer Epidemiology. Prostate Cancer Epidemiology
Prostate Cancer Anatomy Paul A. Godley, MD, PhD Cancer Incidence, Males Prostate Cancer Epidemiology 24 Estimated New Cancer Cases Melanoma 29,9 Oral 18,55 Stomach 13,4 Leukemias 19,2 Kidney 22,8 Lymphomas
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationTable 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationIncidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study
Incidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study Helga Bjork Palsdottir, Sverrir Hardarson, Vigdis Petursdottir, Armann Jonsson,
More informationEpidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
More informationCONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA
CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA Stephen A. Boorjian, MD Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester,
More informationanalyses relied on T stage, Fuhrman grade and presence of enm. Data were analysed using univariable, multivariable and stratified analyses.
. 2008 BJU INTERNATIONAL Urological Oncology EFFECT OF EXCLUSIVE DAL METASTASES ON CSS OF PATIENTS WITH RCC DIFFERS WITH T STAGE CAPITANIO et al. BJUI BJU INTERNATIONAL Stage-specific effect of nodal metastases
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationPARANEOPLASTIC SIGNS AND SYMPTOMS OF RENAL CELL CARCINOMA: IMPLICATIONS FOR PROGNOSIS
0022-5347/03/1705-1742/0 Vol. 170, 1742 1746, November 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000092764.81308.6a PARANEOPLASTIC
More informationLouisiana Cancer Facts & Figures Kidney Cancer 2016
Louisiana Cancer Facts & Figures Kidney Cancer 2016 Louisiana Tumor Registry April 2016 1 Louisiana Tumor Registry Cancer Facts & Figures, Kidney Cancer 2016 Contents Contents: Table of Contents Introduction
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationchapter 5. Quality control at the population-based cancer registry
chapter 5. Quality control at the population-based cancer registry All cancer registries should be able to give some objective indication of the quality of the data that they have collected. The methods
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationREFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - EPIDEMIOLOGY FORECAST TO 2023
REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - Executive Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationResearch Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma
Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,
More informationRenal cell carcinoma in India demonstrates early age of onset & a late stage of presentation
Indian J Med Res 140, November 2014, pp 624-629 Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation Shalini Agnihotri, Jatinder Kumar, Manoj Jain *, Rakesh Kapoor
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationSingapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO)
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013 National Registry of Diseases Office (NRDO) Released November 3, 2014 Acknowledgement This report was
More informationDisparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance
Disparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance Acknowledgements and Disclaimer The collection of cancer incidence data used in this
More informationSocial inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationElectronic health records to study population health: opportunities and challenges
Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu
More informationPattern of metastases in renal cell carcinoma: a single institution study
Original Article Pattern of metastases in renal cell carcinoma: a single institution study Sivaramakrishna B, Gupta Narmada P, Wadhwa P, Hemal Ashok K, Dogra Prem N, Seth A, Aron M, Kumar R Department
More informationA New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
More informationClinical trial enrollment among older cancer patients
Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationCancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?
Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationDifferences in type of comorbidity and complications in young and elderly
Differences in type of comorbidity and complications in young and elderly 5.1 Relation between age, comorbidity, and complications in patients undergoing major surgery for head and neck cancer Peters TTA
More informationSurvival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
More informationObesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH
Obesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH Professor and Martin D. Abeloff, MD Scholar in Cancer Prevention Department of Epidemiology, Johns Hopkins Bloomberg School
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationMissing data and net survival analysis Bernard Rachet
Workshop on Flexible Models for Longitudinal and Survival Data with Applications in Biostatistics Warwick, 27-29 July 2015 Missing data and net survival analysis Bernard Rachet General context Population-based,
More informationTips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD
Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationScreening for Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
More informationCorporate Medical Policy
Corporate Medical Policy Proteomics-based Testing Related to Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomics_based_testing_related_to_ovarian_cancer 7/2010
More informationSaturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date
MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy
More informationA Comparison of Endoscopic Treatment and Surgery in Early Esophageal Cancer: An Analysis of Surveillance Epidemiology and End Results Data
American Journal of Gastroenterology ISSN 0002-9270 C 2008 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2008.01889.x Published by Blackwell Publishing ORIGINAL CONTRIBUTIONS Esophagus A Comparison
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More informationREFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023
REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA Executive Summary Multiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th
More informationBRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
More informationCarcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
More informationReport with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
More informationCollection and Use of Industry and Occupation Data III: Cancer surveillance findings among construction workers
Collection and Use of Industry and Occupation Data III: Cancer surveillance findings among construction workers Geoffrey M. Calvert, MD, MPH, FACP National Institute for Occupational Safety and Health
More informationChapter 2 History of MD Anderson s Tumor Registry
Chapter 2 History of MD Anderson s Tumor Registry Sarah H. Taylor The Tumor Registry Department at The University of Texas MD Anderson Cancer Center is responsible for a database that contains demographic
More informationHepatocellular Carcinoma: What the hepatologist wants to know
Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have
More informationDoes Resection of an Intact Breast Primary Improve Survival in Metastatic Breast Cancer?
rvival in Metastatic Breast Cancer? Review Article [1] July 01, 2007 By Seema A. Khan, MD [2] The recommended primary treatment approach for women with metastatic breast cancer and an intact primary tumor
More informationThe Ontario Cancer Registry moves to the 21 st Century
The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer
More informationSARCOMATOID DIFFERENTIATION IN RENAL CELL CARCINOMA: PROGNOSTIC IMPLICATIONS
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology SARCOMATOID DIFFERENTIATION IN RCC Vol. 31 (1): 101, January February, 2005 SARCOMATOID DIFFERENTIATION IN
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationIn 2006 approximately 234,000 men were diagnosed with
Long-Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy A Propensity Scoring Approach Ashutosh Tewari,*, George
More informationHistologic Subtypes of Renal Cell Carcinoma
Histologic Subtypes of Renal Cell Carcinoma M. Scott Lucia, MD Associate Professor Chief of Genitourinary and Renal Pathology Director, Prostate Diagnostic Laboratory Dept. of Pathology University of Colorado
More informationTreatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
More information